The Circulating Cell-Free DNA (ccfDNA) Diagnostics Market Size is valued at 5130.0 Million in 2022 and is predicted to reach 18202.2 Million by the year 2031 at a 15.2 % CAGR during the forecast period for 2023-2031.
Circulating cell-free DNA is defined as DNA fragments released in the bloodstream for essential and chronic disorders. ccfDNA, also known as circulating DNA (ctDNA), has recently gained popularity as a non-invasive illness biomarker. The scientific community's interest in therapeutic applications of ctDNA continues to grow at an exponential rate, fueling its attractiveness as a viable target in a wide range of study domains. One of the primary drivers of the Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market is the growing concern for early cancer detection. Other drivers include the success of NIPTs, increased cancer prevalence, and an increase in research and development initiatives to investigate the usefulness of circulating biomarkers in disease diagnosis. Furthermore, advances in molecular technology are promoting the exploration of cfDNA as a possible tool for the creation of minimally invasive diagnostics. The use of cfDNA-based diagnostics enhances both informed clinical decision-making and patient outcomes.
However, lack of standardization, poor reimbursement policies, and legal and regulatory restrictions are among the factors impeding market expansion. The dearth of awareness among people in underdeveloped nations is also hindering market expansion.
Market Segmentation:
The Circulating Cell-Free DNA (ccfDNA) Diagnostics market is segmented on the basis of components, Application and end-users. Based on Application, the market is segmented into Non-invasive Prenatal Testing, Cancer Diagnostics, and Others. Based on End-Use, the market is segmented into Hospitals & Prenatal Clinics, Diagnostic Centers, Academic & Government Institutes, Biotechnology & Pharmaceutical Companies.
Based On Non-Invasive Prenatal Testing, The Virtual Reality Headset Segment Is Accounted As A Major Contributor In The Circulating Cell-Free DNA (Ccfdna) Diagnostics Market.
The market for circulating cell-free DNA (ccfDNA) diagnostics is expected to be dominated by non-invasive prenatal testing in terms of revenue. The dominance of this market has been aided by the popularity of non-invasive tests based on cfDNA. Furthermore, the segment is being driven by increased medical coverage for NIPTs. A non-invasive DNA testing process without the hazards associated with amniocentesis or CVS (chorionic villus sample). One of the major aspects driving this segment's revenue growth is increasing knowledge of the procedure's benefits. On the other hand, the category for cancer diagnostics is anticipated to develop the fastest. The main engine of segment expansion is rising investment in the creation of liquid biopsies.
Hospital & Prenatal Clinics Segment Witnessed Growth At A Rapid Rate
The hospitals & prenatal clinics segment is anticipated to gain the major share of the global circulating cell-free DNA (ccfDNA) diagnostics market in the forecast period. The public's understanding and acceptance of non-invasive prenatal DNA screening is growing, which has boosted this sector's income flow. Hospitals & prenatal clinics remain the leading end-users of the market due to the benefits of NIPTs, such as early risk diagnosis of chromosomal defects like down syndrome and trisomy utilizing NIPTs. However, the fastest expanding end-user of this industry is emerging to be the biotechnology and pharmaceutical industries. The primary driver of this category is the recent approval of companion diagnostics.
The North America Circulating Cell-Free DNA (Ccfdna) Diagnostics Market Holds A Significant Revenue Share In The Region.
Competitive Landscape
Some major key players in the Circulating Cell-Free DNA (ccfDNA) Diagnostics Market:
- Hoffmann-La Roche,
- Natera Inc.,
- Illumina Inc.,
- Agena Bioscience,
- Paragon Genomics,
- Thermo Fisher Scientific,
- Bio-Rad Laboratories,
- Lucence Health,
- Eurofins
Circulating Cell-Free DNA (ccfDNA) Diagnostics Market Report Scope
|
Report Attribute |
Specifications |
|
Market size value in 2022 |
USD 5130.0 Million |
|
Revenue forecast in 2031 |
USD 18202.2 Million |
|
Growth rate CAGR |
CAGR of 15.2 % from 2023 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
By Application, By End-Use |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Hoffmann-La Roche, Natera Inc., Illumina Inc., Agena Bioscience, Paragon Genomics, Thermo Fisher Scientific, Bio-Rad Laboratories, Lucence Health, and Eurofins. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
